Diabetic Retinopathy News and Research RSS Feed - Diabetic Retinopathy News and Research

In the initial stages, people with diabetic retinopathy may not notice their vision changing. Diabetics sometimes experience rapid changes in blood sugar that can temporarily cause blurry vision even when retinopathy is not present. If a person notices a few specks or spots floating in his visual field, this may mean he has developed proliferative diabetic retinopathy, the growth of abnormal new blood vessels on the retina and optic nerve. High blood sugar levels have been linked in studies to retinal blood vessel abnormalities. Blurred vision may occur when the macula--the small area at the center of the retina--swells as it fills with fluid that has leaked from retinal blood vessels. Because damage to the eye often develops slowly, early detection of diabetes and control of blood sugar through diet and medications can make a crucial difference in saving vision.

Effective diabetic retinopathy treatments include laser photocoagulation for early to moderate stages and a microsurgery called vitrectomy for repair of eyes with extensive damage. Injectable and oral medications that act on abnormal blood vessels to control diabetic retinopathy before vision loss occurs are now in development. Early detection would be key to the effectiveness of these treatments, also.
3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million. [More]
Current and new treatments for AMD: an interview with Dr Alan Cruess, AMD Alliance International

Current and new treatments for AMD: an interview with Dr Alan Cruess, AMD Alliance International

For two decades beginning in the late 1970’s through 2001, clinicians relied upon laser photocoagulation in the treatment of wet AMD caused by choroidal neovascularization. Attempts to obliterate the neovascular lesions often led to acute central visual loss and often, even with modest success, the lesions recurred with even more vision loss. [More]
Gene therapy provides life-long protection to photoreceptor cells in animal model of retinitis pigmentosa

Gene therapy provides life-long protection to photoreceptor cells in animal model of retinitis pigmentosa

A collaboration between scientists in the UK and the USA has shown that gene therapy can give life-long protection to the light-sensitive photoreceptor cells responsible for colour vision in a mouse model of the most common inherited eye disorder. [More]
OphthaliX updates website to reflect proposed acquisition of Israel-based Improved Vision Systems

OphthaliX updates website to reflect proposed acquisition of Israel-based Improved Vision Systems

OphthaliX Inc., a clinical-stage company focused on developing products that treat and improve sight for people living with ophthalmic disorders, and a subsidiary of Can-Fite BioPharma Ltd., announced today it has launched an updated website, www.ophthaliX.com, to reflect its definitive agreement to acquire Israel-based Improved Vision Systems Ltd. [More]
Retinal function, structure changes in proliferative diabetic retinopathy revealed

Retinal function, structure changes in proliferative diabetic retinopathy revealed

Patients with proliferative diabetic retinopathy exhibit marked visual dysfunction and structural changes in both the inner and outer retinal layers, research findings indicate. [More]

Macular atrophy predicts vision in ranibizumab-treated exudative AMD patients

Progression and severity of macular atrophy are the main anatomical determinants of long-term visual outcomes in exudative age-related macular degeneration patients treated with ranibizumab, suggest SEVEN-UP study results. [More]
Darapladib shows promise in diabetic macular oedema

Darapladib shows promise in diabetic macular oedema

Placebo-controlled trial findings show that lipoprotein-associated phospholipase A2 inhibition modestly benefits the vision of patients with centre-involved diabetic macular oedema and warrants further investigation. [More]
Vitrectomy scatter photocoagulation linked to peripheral thickening in diabetic retinopathy

Vitrectomy scatter photocoagulation linked to peripheral thickening in diabetic retinopathy

Early transient peripheral retinochoroidal thickening following pars plana vitrectomy for proliferative diabetic retinopathy may be related to intraoperative scatter photocoagulation, suggest researchers. [More]

ORT incidence increases in nAMD despite anti-VEGF treatment

Swiss researchers report that patients with neovascular age-related macular degeneration (nAMD) experience increased incidence of outer retinal tubulation over time, despite treatment with a vascular endothelial growth factor blocker. [More]
Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO). [More]
Researchers advance stem cell therapy to block vision loss caused by diabetic retinopathy

Researchers advance stem cell therapy to block vision loss caused by diabetic retinopathy

University of Virginia School of Medicine researchers have taken a significant step forward in their efforts to use stem cells to block vision loss caused by diabetic retinopathy, a condition that affects millions of people with diabetes. [More]
Innovative formula prevents risks, painful treatments in people with secondary blindness

Innovative formula prevents risks, painful treatments in people with secondary blindness

The Mexican company "Medical and Surgical Center for Retina" created a way to transport drugs, in order to avoid risks and painful treatments in people with secondary blindness due to chronic degenerative blindness such as diabetic retinopathy and degeneration of the eye. [More]

OphthaliX enters into definitive agreement to purchase Improved Vision Systems

OphthaliX Inc., a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd., announced today it has signed a definitive agreement to acquire Israel-based Improved Vision Systems Ltd. in a stock-for-stock transaction. [More]
Medicare physician reimbursement data could be confusing to the public

Medicare physician reimbursement data could be confusing to the public

The Centers for Medicare & Medicaid Services today released to the public data relating to 2013 Medicare payments made to physicians and other providers. In response, the American Academy of Ophthalmology is providing necessary context for the reimbursement data, which in its raw form are often complex and difficult to understand. [More]
Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the three months ended March 31, 2015 and updates on its drug development programs. [More]
Metformin can reduce risk of open-angle glaucoma in people with diabetes

Metformin can reduce risk of open-angle glaucoma in people with diabetes

Taking the medication metformin hydrochloride was associated with reduced risk of developing the sight-threatening disease open-angle glaucoma in people with diabetes, according to a study published online by JAMA Ophthalmology. [More]
Study could offer new way to treat, prevent diabetes-associated blindness

Study could offer new way to treat, prevent diabetes-associated blindness

Reporting on their study with lab-grown human cells, researchers at The Johns Hopkins University and the University of Maryland say that blocking a second blood vessel growth protein, along with one that is already well-known, could offer a new way to treat and prevent a blinding eye disease caused by diabetes. [More]

Submacular air injection aids tPA haemorrhage displacement

Submacular air injection with a microneedle is effective at facilitating the displacement of massive submacular haemorrhages dissolved with tissue plasminogen activator in patients with age-related macular degeneration, an interventional case series shows. [More]
OAO report calls for better care for people living with eye disease, vision problems in Ontario

OAO report calls for better care for people living with eye disease, vision problems in Ontario

By 2031, the number of Ontarians living with eye disease and vision problems, already in the millions, is expected to double. This leads to significant costs for Ontario's healthcare system, with vision loss already costing the province $7.3 billion annually. [More]
TSRI study provides new insight into preventing diseases that cause vision loss in adults

TSRI study provides new insight into preventing diseases that cause vision loss in adults

A new study from scientists at The Scripps Research Institute shows that nerve cells and blood vessels in the eye constantly "talk" to each other to maintain healthy blood flow and prevent disease. [More]
Advertisement
Advertisement